1. Home
  2. JTAI vs DCOY Comparison

JTAI vs DCOY Comparison

Compare JTAI & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$9.04

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$8.60

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JTAI
DCOY
Founded
2018
N/A
Country
United States
United States
Employees
8
11
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
DCOY
Price
$9.04
$8.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$80.00
$30.00
AVG Volume (30 Days)
161.8K
9.2K
Earning Date
05-15-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.53
52 Week High
$10.41
$9.09

Technical Indicators

Market Signals
Indicator
JTAI
DCOY
Relative Strength Index (RSI) 66.84 68.27
Support Level $6.03 $5.28
Resistance Level $9.24 $9.09
Average True Range (ATR) 0.69 0.79
MACD 0.10 0.36
Stochastic Oscillator 88.29 74.90

Price Performance

Historical Comparison
JTAI
DCOY

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: